Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 7/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.73 |
| ▸ | TP53 | P04637 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896188 | 0.91 | POLB (0.76) | ALDH1A1LMNAPOLBTP53KMT2A | |
| SCHEMBL16903565 | 0.85 | MAPT (0.80) | LMNATP53MAPTTHRB | |
| SCHEMBL16896230 | 0.85 | TP53 (0.73) | ALDH1A1LMNAKDM4EPOLBTP53 | |
| SCHEMBL16903570 | 0.84 | MAPT (0.66) | ALDH1A1LMNAKDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL16896033 | 0.84 | LMNA (0.70) | ALDH1A1LMNAPOLBTP53MAPT | |
| SCHEMBL5992944 | 0.83 | POLB (0.86) | ALDH1A1LMNAKDM4EPOLBTP53 | |
| SCHEMBL20089845 | 0.82 | LMNA (0.68) | ALDH1A1LMNAPOLBTP53MAPT | |
| SCHEMBL16896201 | 0.82 | TP53 (0.69) | ALDH1A1LMNAKDM4EPOLBTP53 | |
| SCHEMBL16896197 | 0.82 | LMNA (0.68) | ALDH1A1LMNAPOLBTP53MAPT | |
| SCHEMBL16896219 | 0.81 | LMNA (0.82) | LMNAPOLBTP53KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152188-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | disclosed |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152188-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | TLR7, TLR4, TLR3 | ALDH1A1 4634/4885LMNA 1496/4885KDM4E 3146/4885 |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | TLR4, TLR9, TLR1 | ALDH1A1 2429/4885LMNA 1948/4885KDM4E 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.